PHF12 Inhibitors
Chemical inhibitors of PHF12 can lead to changes in the regulation of gene expression by affecting the protein's interaction with chromatin. Trichostatin A, Mocetinostat, Entinostat, Vorinostat, Romidepsin, Panobinostat, Belinostat, Chidamide, Valproic Acid, Sodium Butyrate, Tacedinaline, and Pracinostat are compounds that inhibit histone deacetylases (HDACs), enzymes with which PHF12 is known to associate. The inhibition of HDACs results in the increased acetylation of histones. This hyperacetylated state of histones induced by the inhibitors can disrupt the normal function of PHF12 in chromatin remodeling. As acetylation of histones typically leads to a more open chromatin structure, this change can interfere with the ability of PHF12 to modulate chromatin in its usual capacity, affecting its role in the regulation of gene expression.
The specific action of these inhibitors varies, but they all converge on the alteration of the chromatin landscape by changing the acetylation pattern of histones. For instance, Trichostatin A and Vorinostat are broad-spectrum HDAC inhibitors, affecting a wide range of HDAC classes, thereby broadly impacting the acetylation status of histones and non-histone proteins. In contrast, Entinostat selectively inhibits class I HDACs, potentially offering a more targeted alteration of acetylation patterns relevant to PHF12's activities. Other compounds, such as Romidepsin and Panobinostat, while also acting as HDAC inhibitors, may have distinct effects due to differences in their structure and affinity for various HDAC enzymes. Collectively, these chemical inhibitors alter the interaction landscape of PHF12 with chromatin, leading to changes in the structure and function of chromatin that are mediated by the acetylation state of histones.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylase (HDAC), which can increase the acetylation of histones, thereby influencing chromatin structure and affecting gene expression. PHF12 is known to interact with HDACs, suggesting that by inhibiting HDAC, Trichostatin A may disrupt the function of PHF12 as part of a complex that modifies chromatin. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat is another HDAC inhibitor that can lead to hyperacetylation of histones. PHF12 is associated with chromatin remodeling, and the inhibition of HDAC by Mocetinostat can alter the chromatin state, potentially disrupting the ability of PHF12 to properly interact with chromatin and carry out its function. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat selectively inhibits class I HDACs, which could impact PHF12's role in chromatin modulation and gene expression regulation by altering the acetylation status of histones and non-histone proteins that interact with PHF12. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat is a broad-spectrum HDAC inhibitor that can affect the function of PHF12 by changing the acetylation pattern of histones, which are known to interact with PHF12, thus potentially inhibiting PHF12's ability to exert its role in chromatin remodeling and gene expression. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin functions as an HDAC inhibitor, specifically impacting the acetylation levels of histones. As PHF12 has been implicated in histone modification through its association with HDACs, the inhibition of HDAC activity by Romidepsin could disrupt PHF12's function in chromatin structure regulation. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is a potent HDAC inhibitor that can lead to an altered acetylation landscape of histones. Given that PHF12 interacts with chromatin through histone modification, the inhibition of HDAC by Panobinostat could interfere with the chromatin-related functions of PHF12. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat inhibits HDAC activity, consequently modifying the acetylation status of histones. As PHF12's function is associated with chromatin remodeling, Belinostat's action on HDAC could impair PHF12's ability to interact with chromatin and regulate gene expression. | ||||||
Chidamide | 743420-02-2 | sc-364462 sc-364462A sc-364462B | 1 mg 5 mg 25 mg | $62.00 $250.00 $1196.00 | ||
Chidamide is an HDAC inhibitor that affects chromatin structure and function by altering histone acetylation, potentially impacting PHF12's role in chromatin organization and function due to PHF12's association with chromatin remodeling complexes. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid is a weak HDAC inhibitor which can cause hyperacetylation of histones, potentially affecting the chromatin interactions of PHF12 and thereby its function in gene expression regulation. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate acts as an HDAC inhibitor leading to changes in histone acetylation, which could disrupt the role of PHF12 in chromatin remodeling and gene regulation by altering the acetylation status of histones that PHF12 interacts with. | ||||||